Angel S Galabov1, Milka Mileva2, Lora Simeonova2, Galina Gegova2. 1. The Stephan Angeloff Institute of Microbiology, Bulgarian Academy of Sciences, Sofia, Bulgaria galabov@microbio.bas.bg. 2. The Stephan Angeloff Institute of Microbiology, Bulgarian Academy of Sciences, Sofia, Bulgaria.
Abstract
BACKGROUND: Influenza is a highly contagious viral infection of the respiratory system. To attack two processes involved in flu pathogenesis-viral replication in the infected body and oxidative damages, we studied the combination effect of neuraminidase inhibitor oseltamivir and antioxidant α-tocopherol in experimental model of influenza. METHODS: After inoculation of albino mice with 10 MLD50 (50% mouse lethal dose) of influenza virus A/Aichi/2/68 (H3N2), oseltamivir was applied orally at three doses, 2.5 mg/kg, 1.25 mg/kg, and 0.625 mg/kg, for five days post infection. α-Tocopherol (120 mg/kg, in sunflower oil) was administered intraperitoneally. Three schemes of α-tocopherol five-day course were tested: onset five or two days before infection, or on the virus inoculation day. RESULTS: Strongly dose-dependent augmented antiviral effect of the combination α-tocopherol and 0.625 mg/kg oseltamivir was demonstrated when α-tocopherol was administered simultaneously with oseltamivir: a pronounced decrease in mortality rate (a 78% protection), and a lengthening of mean survival time by 3.2-4 days. Lung parameters showed a substantial decrease in infectious virus content (Δ logs = 3.8/4.1) and a marked diminishment of lung index and pathology. Combination α-tocopherol with 1.25 mg/kg oseltamivir manifested a marked protective effect, but the effect on lung parameters was less. The combination effect of α-tocopherol with 2.5 mg/kg oseltamivir did not surpass the monotherapeutic effect of oseltamivir. When α-tocopherol was applied in courses starting five or two days before infection, its combination with oseltamivir was ineffective. CONCLUSIONS: Evidently, α-tocopherol could be considered as prospective component of influenza therapy in combination with oseltamivir.
BACKGROUND:Influenza is a highly contagious viral infection of the respiratory system. To attack two processes involved in flu pathogenesis-viral replication in the infected body and oxidative damages, we studied the combination effect of neuraminidase inhibitor oseltamivir and antioxidant α-tocopherol in experimental model of influenza. METHODS: After inoculation of albino mice with 10 MLD50 (50% mouse lethal dose) of influenza virus A/Aichi/2/68 (H3N2), oseltamivir was applied orally at three doses, 2.5 mg/kg, 1.25 mg/kg, and 0.625 mg/kg, for five days post infection. α-Tocopherol (120 mg/kg, in sunflower oil) was administered intraperitoneally. Three schemes of α-tocopherol five-day course were tested: onset five or two days before infection, or on the virus inoculation day. RESULTS: Strongly dose-dependent augmented antiviral effect of the combination α-tocopherol and 0.625 mg/kg oseltamivir was demonstrated when α-tocopherol was administered simultaneously with oseltamivir: a pronounced decrease in mortality rate (a 78% protection), and a lengthening of mean survival time by 3.2-4 days. Lung parameters showed a substantial decrease in infectious virus content (Δ logs = 3.8/4.1) and a marked diminishment of lung index and pathology. Combination α-tocopherol with 1.25 mg/kg oseltamivir manifested a marked protective effect, but the effect on lung parameters was less. The combination effect of α-tocopherol with 2.5 mg/kg oseltamivir did not surpass the monotherapeutic effect of oseltamivir. When α-tocopherol was applied in courses starting five or two days before infection, its combination with oseltamivir was ineffective. CONCLUSIONS: Evidently, α-tocopherol could be considered as prospective component of influenza therapy in combination with oseltamivir.
Authors: Kirsty R Short; Dimitri A Diavatopoulos; Ruth Thornton; John Pedersen; Richard A Strugnell; Andrew K Wise; Patrick C Reading; Odilia L Wijburg Journal: J Infect Dis Date: 2011-09-19 Impact factor: 5.226
Authors: M G Hayek; S F Taylor; B S Bender; S N Han; M Meydani; D E Smith; S Eghtesada; S N Meydani Journal: J Infect Dis Date: 1997-07 Impact factor: 5.226
Authors: S N Meydani; M P Barklund; S Liu; M Meydani; R A Miller; J G Cannon; F D Morrow; R Rocklin; J B Blumberg Journal: Am J Clin Nutr Date: 1990-09 Impact factor: 7.045
Authors: Khaled Khoufache; Fatma Berri; Wolfgang Nacken; Annette B Vogel; Marie Delenne; Eric Camerer; Shaun R Coughlin; Peter Carmeliet; Bruno Lina; Guus F Rimmelzwaan; Oliver Planz; Stephan Ludwig; Béatrice Riteau Journal: J Clin Invest Date: 2012-12-03 Impact factor: 14.808